IMMP is Immutep Limited (Healthcare) — a non-dividend-paying stock. Trading at $0.36. Market cap: $54M.
Stock snapshot
| Price | $0.36 |
| Market cap | $54M |
| Sector | Healthcare |
| Exchange | NGM |
| Pays dividend | No |
About IMMP
Immutep Ltd is a clinical-stage biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.
Frequently asked
What is IMMP's current stock price?
IMMP (Immutep Limited) is currently trading at $0.36.
Does IMMP pay a dividend?
IMMP (Immutep Limited) does not currently pay a regular dividend.
Track IMMP in DiviDrip
Add IMMP to your watchlist on DiviDrip to monitor price, fundamentals, and Capital Quality Rank week-over-week. Built for long-term investors tracking both dividend and non-dividend names.
- Open DiviDrip — search IMMP and add it to your watchlist.
- Stock Screener — filter by sector, market cap, and Capital Quality Rank.
- How to use the Screener — sector / quality / market-cap filters explained.
Data refreshed 2026-09-05. Not investment advice. Prices change continuously; always verify the latest numbers in the live app before buying.